Compare TWI & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | GYRE |
|---|---|---|
| Founded | 1890 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.3M | 759.1M |
| IPO Year | 1997 | 2004 |
| Metric | TWI | GYRE |
|---|---|---|
| Price | $6.80 | $6.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 853.3K | 129.2K |
| Earning Date | 04-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $3.69 | $19.88 |
| Revenue Next Year | $4.85 | N/A |
| P/E Ratio | ★ N/A | $352.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.93 | $6.11 |
| 52 Week High | $11.70 | $11.77 |
| Indicator | TWI | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 26.16 | 38.73 |
| Support Level | N/A | N/A |
| Resistance Level | $9.18 | $8.25 |
| Average True Range (ATR) | 0.39 | 0.40 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 2.46 | 11.98 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. The company operates through three segments namely Agricultural, Earthmoving/Construction, and Consumer. Geographically, business of the group can be seen in the United States, Europe / CIS, Latin America and Other international. Titan derives majority of the revenue from Agricultural segment which manufacture various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment, and are sold directly to original equipment manufacturers and to the aftermarket through independent distributors, equipment dealers and Titan's own distribution centers.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.